GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Phase 3

Amycretin

Company
Novo Nordisk
Mechanism
dual GLP-1/amylin
Route
Oral & injectable
Recruiting trials
None currently listed
24.3% Absolute change weight loss · 36 weeks · Adults with overweight or obesity · Phase 1b/2a (subcutaneous)

Next milestone: AMAZE-1 Phase 3 readout

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT06049329

    A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

    Not yet reported Novo Nordisk A/S 36 participants Est. completion 2023-12-15 1 site
    Other conditions: Obesity
    View official trial listing →
Efficacy history
24.3%

Absolute change weight loss · 36 weeks

Adults with overweight or obesity

Trial: Phase 1b/2a (subcutaneous) (Phase 2)

Source →
13.1%

Absolute change weight loss · 12 weeks

Adults with overweight or obesity

Trial: Phase 1 (oral) (Phase 1)

Source →

Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.